Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease

Han,Bing; Wang,Qingli

doi:10.3892/etm.2018.6310

Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease

Authors:
- Bing Han
- Qingli Wang
View Affiliations

Affiliations: The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Internal Medicine Cardiovascular Department, The Sixth People's Hospital of Jinan, Jinan, Shandong 250200, P.R. China
Published online on: June 13, 2018 https://doi.org/10.3892/etm.2018.6310
Pages: 1175-1186
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pulmonary hypertension due to left heart disease (PH‑LHD) is caused by left ventricular (LV) systolic and/or diastolic dysfunction and left heart valve disease. LV diseases lead to left ventricular filling pressure increases, pulmonary venous obstruction and pulmonary venous pressure increases, and thus to secondary PH. Exercise tolerance is lower and fatality rates are higher in patients with PH‑LHD than those in subjects with normal pulmonary arterial pressure. In spite of the progress in the study of the mechanisms of PH‑LHD in recent years, no specific treatment is currently available. The efficacy and safety of targeted therapies for pulmonary arterial hypertension remain to be fully established. In the present study, PH‑LHD patients were treated with milrinone injection. It was concluded that milrinone significantly reduces pulmonary artery systolic pressure (PASP) in patients with PH‑LHD, and significantly improves the cardiac structure, cardiac function and biochemical indexes. PASP was significantly correlated with the left atrial diameter, LV end diastolic diameter, LV ejection fraction, tricuspid annular plane systolic excursion, right ventricular fractional area change, N‑terminal pro‑B‑type natriuretic peptide and hypersensitive C‑reactive protein.

View Figures

View References

1	Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, Jiang R and Roger VL: Pulmonary pressures and death in heart failure: A community study. J Am Coll Cardiol. 59:222–231. 2012. View Article : Google Scholar : PubMed/NCBI
2	Barst RJ, Ertel SI, Beghetti M and Ivy DD: Pulmonary arterial hypertension: A comparison between children and adults. Eur Respir J. 37:665–677. 2011. View Article : Google Scholar : PubMed/NCBI
3	Guo H: Applied research of specific phosphodiesterase inhibitor during perioperative period of rheumatic valvular disease combining with pulmonary hypertension (unpublished PhD thesis). Southern Medical University. 2012.
4	Yu Y and Shi J: Effect of milrinone on pulmonary function and dynamics of congenital heart disease with pulmonary hypertension in patients with pulmonary oxygen. J Practical Med. 28:469–470. 2012.
5	Xu D: Effect of milrinone on pulmonary hypertension after cardiac surgery. Guide Chin Med. 11:200–202. 2013.(In Chinese).
6	Yao B, Da G, Li Y, Wu J, Li Z, Yang Y, Zhu J, Wang W and Yang J: The protective effect of milrinone on heart function in plateau region in children with congenital heart disease and pulmonary hypertension after operation. Shandong Med J. 54:49–51. 2014.(In Chinese).
7	Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International society of heart and lung transplantation (ISHLT). Eur Heart J. 30:2493–2537. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yock PG and Popp RL: Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 70:657–662. 1984. View Article : Google Scholar : PubMed/NCBI
9	Trammell AW, Pugh ME, Newman JH, Hemnes AR and Robbins IM: Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. Pulm Circ. 5:356–363. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li A, Xue C, Song M, MA S and Jia W: The clinical efficacy and safety of oral administration of atorvastatin in patients with pulmonary hypertension with left heart disease. Ningxia Med J. 37:319–321. 2015.(In Chinese).
11	Lian X, Yang G and Wang E: Efficacy of levosimendan combined with sildenafil in the treatment of chronic heart failure with pulmonary hypertension. Practical J. 40:14–16. 2013.
12	Shipley JB, Tolman D, Hastillo A and Hess ML: Milrilone: Basic and clinical pharmacology and acute and chronic management. Am J Med Sci. 311:286–291. 1996. View Article : Google Scholar : PubMed/NCBI
13	Schudt C, Winder S, Forderkunz S, Hatzelmann A and Ullrich V: Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol. 344:682–690. 1991. View Article : Google Scholar : PubMed/NCBI
14	Kume M, Banafsche R, Yamamoto Y, Yamaoka Y, Nobiling R, Gebhard MM and Klar E: Dynamic changes of post-ischemic hepatic microcirculation improved by a pre-treatment of phosphodiesterase-3 inhibitor, milrinone. J Surg Res. 136:209–218. 2006. View Article : Google Scholar : PubMed/NCBI
15	Endres S, Sinba B and Fulle HJ: Amrinone suppresses the synthesis of tumor necrosis factor-alpha in human mononuclear cells. Shock. 1:377–380. 1994. View Article : Google Scholar : PubMed/NCBI
16	Kawamura A, Yoshikawa T, Takahashi T, Hayashi T, Takahashi E, Anzai T, Sato T and Ogawa S: Randomized trial of phosphodiesterase inhibitors versus catecholamines in patient with acutely decompensated heart failure. Jpn Circ J. 65:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lanfear DE, Hasan R, Gupta RC, Williams C, Czerska B, Tita C, Bazari R and Sabbah HN: Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. J Transl Med. 29:672009. View Article : Google Scholar
18	Siflinger-Bimboim A, Bode DC and Malik AB: Adenosine 3′,5′-cyclic monophosphate attenuates neutrophil-mediated increase in endothelial permeability. Am J Physiol. 264:H370–H375. 1993.PubMed/NCBI
19	Fleming GA, Murray KT, Yu C, Byrne JG, Greelish JP, Petracek MR, Hoff SJ, Ball SK, Brown NJ and Pretorius M: Milrinone use is associated with post-operative atrial fibrillation after cardiac surgery. Circulation. 118:1619–1625. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lamarche Y, Malo O, Thorin E, Denault A, Carrier M, Roy J and Perrault LP: Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopumonary bypass. J Thorac Cardiovasc Surg. 130:83–92. 2005. View Article : Google Scholar : PubMed/NCBI
21	Burgess MI, Mogulkoc N, Bright-Thomas RJ, Bishop P, Egan JJ and Ray SG: Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. J Am Soc Echocardiogr. 15:633–639. 2002. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Wang Y, Zhai Z, Guo X, Yang Y and Lu X: Real-time three-dimensional echocardiography to assess right ventricle function in patients with pulmonary hypertension. PLoS One. 10:e01295572015. View Article : Google Scholar : PubMed/NCBI
23	Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf Vonk A, Beghetti M, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 37:67–119. 2016. View Article : Google Scholar : PubMed/NCBI
24	Harbaum L, Hennigs JK, Baumann HJ, Lüneburg N, Griesch E, Bokemeyer C, Grünig E and Klose H: N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency. PLoS One. 9:e942632014. View Article : Google Scholar : PubMed/NCBI
25	Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C and Ueland T: N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 98:525–529. 2006. View Article : Google Scholar : PubMed/NCBI
26	Kolditz M, Seyfarth HJ, Wilkens H, Ewert R, Bollmann T, Dinter C, Hertel S, Klose H, Opitz C, Grünig E, et al: MR-proADM predicts exercise capacity and survival superior to other biomarkers in PH. Lung. 193:901–910. 2015. View Article : Google Scholar : PubMed/NCBI
27	Wesley MC, McGowan FX, Castro RA, Dissanayake S, Zurakowski D and Dinardo JA: The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg. 108:1425–1429. 2009. View Article : Google Scholar : PubMed/NCBI
28	Kikura M, Lee MK, Safon RA, Bailey JM and Levy JH: The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg. 81:44–48. 1995. View Article : Google Scholar : PubMed/NCBI
29	Baruch L, Patacsil P, Hameed A, Pina I and Loh E: Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J. 141:266–273. 2001. View Article : Google Scholar : PubMed/NCBI
30	Huang LY and Yang Y: Clinical study of milrinone in the treatment of neonatal persistent pulmonary hypertension. Straits Sci. 8:111–113. 2012.(In Chinese).